Description: <p>Estragole is a cautionary/toxicology-relevant natural product because it is a naturally occurring phenylpropene found in several medicinal/aromatic plants and is widely discussed as a genotoxic carcinogenic concern. EFSA describes estragole in fennel seed preparations as a naturally occurring compound that is genotoxic and carcinogenic, and EMA/HMPC recommends keeping exposure to estragole as low as practically achievable in herbal medicinal products.
</p>
<p><b>Estragole</b> — Estragole is a naturally occurring phenylpropene aromatic compound, also known as methyl chavicol or p-allylanisole, found in tarragon, basil, fennel, anise, star anise, chervil, and related essential oils. It is best classified in this database as a toxicology-relevant natural-product constituent rather than an anticancer therapeutic agent. Its main database relevance is genotoxic carcinogenic risk after metabolic activation, especially from concentrated essential oils or high-estragole herbal preparations.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>CYP-mediated 1′-hydroxylation followed by sulfotransferase bioactivation to reactive 1′-sulfooxyestragole.</li>
<li>Covalent DNA adduct formation and genotoxic initiation, especially in liver-relevant metabolic systems.</li>
<li>Rodent hepatocarcinogenesis after repeated or high-dose exposure, with human relevance inferred from shared metabolic activation pathways.</li>
<li>Direct DNA damage and weak direct-acting genotoxicity in vitro, with apoptosis only at high experimental concentrations.</li>
<li>Competing detoxification pathways such as O-demethylation, oxidation, glucuronidation, and other conjugation routes that reduce relative bioactivation at lower exposures.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Estragole is a small lipophilic volatile compound with oral and dermal exposure relevance. Oral exposure is rapidly metabolized, and the risk-relevant pathway depends on formation of 1′-hydroxyestragole and subsequent sulfoconjugation. Concentrated oils, extracts, supplements, and repeated medicinal use are more relevant than ordinary low culinary exposure.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many in-vitro genotoxicity or cytotoxicity studies use high micromolar to millimolar concentrations that exceed typical dietary spice exposure. However, estragole is treated as a genotoxic carcinogen in risk assessment because DNA-reactive metabolites can form in human-relevant systems, and a safe exposure threshold has not been firmly established by regulators.</p>
<p><b>Clinical evidence status:</b> No credible anticancer clinical use. Evidence status is toxicology/regulatory: rodent carcinogenicity, mechanistic genotoxicity, human metabolite evidence, and regulatory exposure-minimization guidance. Database classification should emphasize hazard, exposure control, and caution with high-estragole essential oils or concentrated herbal medicinal products.</p>
<h3>Estragole Mechanistic Profile</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>CYP and SULT bioactivation</td>
<td>↔ therapeutic relevance unclear</td>
<td>↑ 1′-hydroxyestragole and ↑ reactive sulfate metabolite</td>
<td>R</td>
<td>Metabolic activation</td>
<td>Core hazard mechanism; liver metabolism is central to genotoxic carcinogenicity.</td>
</tr>
<tr>
<td>2</td>
<td>DNA adduct formation</td>
<td>↑ DNA adduct stress (model-dependent)</td>
<td>↑ covalent DNA binding and genotoxic initiation</td>
<td>R/G</td>
<td>Genotoxic carcinogenic risk</td>
<td>Primary database pathway; should be listed as toxic/pro-carcinogenic rather than anticancer.</td>
</tr>
<tr>
<td>3</td>
<td>Hepatocarcinogenesis</td>
<td>↔ not a treatment mechanism</td>
<td>↑ liver tumor risk in rodent high-dose/repeated exposure models</td>
<td>G</td>
<td>Tumor initiation and promotion risk</td>
<td>Rodent liver tumor evidence drives regulatory concern; human risk is inferred through shared metabolic activation.</td>
</tr>
<tr>
<td>4</td>
<td>DNA damage response and apoptosis</td>
<td>↑ apoptosis only at high concentration</td>
<td>↑ DNA damage stress (dose-dependent)</td>
<td>G</td>
<td>Nonselective cytotoxic stress</td>
<td>In-vitro apoptosis findings are not a practical anticancer rationale because they occur at high exposure and are outweighed by genotoxic risk.</td>
</tr>
<tr>
<td>5</td>
<td>NRF2 sensitization assay signal</td>
<td>↔ unclear</td>
<td>↑ ARE-NRF2 reporter signal in skin-sensitization testing</td>
<td>R/G</td>
<td>Electrophile/stress-response signal</td>
<td>NRF2 is not a core anticancer mechanism here; it appears mainly in hazard testing for sensitization or reactive chemistry.</td>
</tr>
<tr>
<td>6</td>
<td>Detoxification competition</td>
<td>↔ context-dependent</td>
<td>↑ detoxification via O-demethylation and conjugation pathways</td>
<td>R</td>
<td>Risk modulation</td>
<td>Low-dose risk may be reduced by competing detoxification, but this does not establish a safe threshold.</td>
</tr>
<tr>
<td>7</td>
<td>Clinical Translation Constraint</td>
<td>Not suitable as anticancer product</td>
<td>Genotoxic carcinogen concern; avoid concentrated exposure</td>
<td>G</td>
<td>Regulatory and safety limitation</td>
<td>Database use should emphasize toxicology, exposure minimization, and caution with fennel oil, anise oil, star anise oil, basil oil, and tarragon oil sources.</td>
</tr>
</tbody>
</table>
<p>TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr</p>